Pneumonia
Drug research and approvals for pneumonia: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 599 studies of pneumonia are recruiting on ClinicalTrials.gov, Health Canada has authorized 16 drug trials for it since 2013, FDA has 6 approved and 14 open orphan designations naming it, and the EU has 14 authorised medicines for it.
- Recruiting worldwide: 599
- Trials authorized in Canada: 16
- FDA orphan approvals: 6
- EU medicines: 14
- Improving Vaccine Efficacy for People With Helminth Infection: CORBEVAX in EthiopiaNCT07948395 · Phase 2 / Phase 3 · University of Aarhus · starts Oct 10, 2026
- A Superiority Study of Model-Guided Optimized Dosing Versus Empirical Dosing of Piperacillin/Tazobactam in the…NCT07945275 · Phase 2 · Shandong University · starts Jul 17, 2026
- Effect of Single High-Dose Vitamin D3 Versus Placebo on Hospital Length of Stay in Children With Severe Pneumonia.NCT07938489 · Not applicable · Shaheed Mohtarma Benazir Bhutto Institue of Trauma · starts Jul 1, 2026
- Exploring the Extended Efficacy and Initial Use of RUCONEST® in Managing Neurological Symptoms Linked to Infectious…NCT07932002 · Phase 4 · IMMUNOe Research Centers · starts Nov 5, 2025
- CEDRN Pandemic Preparedness RegistryNCT07933861 · Not reported · University of British Columbia · starts Sep 1, 2026
- Respiratory Physiotherapy and Inflammatory Biomarkers in Critically Ill Patients With PneumoniaNCT07909616 · Not reported · Hospital H+ Queretaro · starts Sep 8, 2026
- The Effects of Wintergreen Essential Oil Inhalation on Alleviating Dyspnea Among Patients With PneumoniaNCT07894835 · Not applicable · Far Eastern Memorial Hospital · starts Oct 19, 2026
- A Multicenter Randomized Trial of CT-Based AI Decision Support for Early Pneumonia CareNCT07895290 · Not applicable · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · starts Jan 1, 2026
- Whole-body Cryotherapy in Those With Chronic Fatigue: A Feasibility StudyNCT07874217 · Not applicable · Oxford Brookes University · starts Oct 5, 2026
Approved 24 of 32
- AmoxicillinBacterial penicillin-binding protein inhibitor
- LevofloxacinDNA gyrase inhibitor
- AzithromycinBacterial 70S ribosome inhibitor
- LinezolidBacterial 70S ribosome inhibitor
- MoxifloxacinTopoisomerase IV inhibitor
- ClarithromycinBacterial 70S ribosome inhibitor
- CeftazidimeBacterial penicillin-binding protein inhibitor
- DexamethasoneGlucocorticoid receptor agonist
- TazobactamBacterial beta-lactamase TEM inhibitor
- ImipenemBacterial penicillin-binding protein inhibitor
- TelithromycinBacterial 70S ribosome inhibitor
- PrednisoneGlucocorticoid receptor agonist
- Clavulanic acidBacterial beta-lactamase TEM inhibitor
- PiperacillinBacterial penicillin-binding protein inhibitor
- Ascorbic acidSupplement
- DoxycyclineMatrix metalloproteinase 7 inhibitor
- MetronidazoleDNA inhibitor
- CilastatinRenal dipeptidase inhibitor
- CefuroximeBacterial penicillin-binding protein inhibitor
- CefdinirBacterial penicillin-binding protein inhibitor
- BacitracinC55-isoprenyl pyrophosphate inhibitor
- CefoxitinBacterial penicillin-binding protein inhibitor
- Clindamycin phosphateBacterial 70S ribosome inhibitor
- FoscarnetHuman herpesvirus 1 DNA polymerase inhibitor
Phase 3 12 of 65
- CeftriaxoneBacterial penicillin-binding protein inhibitor
- NemonoxacinBacterial DNA gyrase inhibitor
- MeropenemBacterial penicillin-binding protein inhibitor
- ColistinCell outer membrane inhibitor
- Ceftobiprole medocaril free acidPenicillin-binding protein 1 inhibitor
- BaricitinibTyrosine-protein kinase JAK1 inhibitor
- HeparinAntithrombin-III activator
- SimvastatinHMG-CoA reductase inhibitor
- CeftolozaneBacterial penicillin-binding protein inhibitor
- Zinc sulfate
- CiprofloxacinBacterial DNA gyrase inhibitor
- TicagrelorPurinergic receptor P2Y12 negative allosteric modulator
Phase 2 12 of 16
- AmikacinBacterial 70S ribosome inhibitor
- CaptoprilAngiotensin-converting enzyme inhibitor
- NeomycinBacterial 70S ribosome inhibitor
- Polymyxin bCell outer membrane inhibitor
- TofacitinibJanus Kinase (JAK) inhibitor
- BevacizumabVascular endothelial growth factor A inhibitor
- EptifibatideIntegrin alpha-IIb/beta-3 inhibitor
- NystatinErgosterol sequestering agent
- ColistimethateCell membrane inhibitor
- Albumin humanBilirubin sequestering agent
- RadezolidBacterial 70S ribosome inhibitor
- AR-105Alginate polysaccharide binding agent
Phase 1 or earlier 12 of 15
- DelafloxacinBacterial DNA gyrase inhibitor
- RuxolitinibTyrosine-protein kinase JAK1 inhibitor
- CholecalciferolVitamin D receptor agonist
- MinocyclineBacterial 70S ribosome inhibitor
- FostamatinibTyrosine-protein kinase SYK inhibitor
- KBPA-101Lipopolysaccharide (LPS) inhibitor
- KB-001Low calcium response locus protein V inhibitor
- Sulopenem etzadroxilBacterial penicillin-binding protein inhibitor
- SulopenemBacterial penicillin-binding protein inhibitor
- CeftobiproleBacterial penicillin-binding protein inhibitor
- GremubamabLow calcium response locus protein V inhibitor
- Dextrose
How its trials ended
2,022 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 447 whose ending is known, 38% met their primary endpoint, 13% missed it and 48% stopped early.
- Completed, result not reported84742%
- Status unknown41521%
- Ongoing31315%
- Met its primary endpoint1729%
- Stopped: other or unclear1387%
- Missed its primary endpoint593%
- Stopped: enrollment or feasibility362%
- Stopped: lack of efficacy191%
- Stopped: sponsor or business decision151%
- Stopped: funding6<1%
- Stopped: safety2<1%
| Sep 1, 2026 | Global unified adaptive research on acute care diseases –respiratory infections (guard-resp)Dexamethasone | University of Manitoba | Pending |
| Feb 26, 2026 | Microbiome-guided prophylaxis to reduce ventilator-associated pneumonia in intensive care units (micro-vap): a pilot randomized controlled trialTobramycin / Vancomycin / Aztreonam | Governors of The University of Calgary | Pending |
| Aug 26, 2024 | Targeting vascular inflammation in patients with community acquired pneumonia: a multi-centre, prospective, randomized control trialIcosapent ethyl / 18F-fluorodeoxyglucose | Ottawa Heart Institute Research Corporation | Pending |
| Jul 17, 2024 | A phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of adjunctive recombinant human plasma gelsolin with standard…Recombinant human plasma gelsolin (rhu-pgsn) | BioAegis Therapeutics | Ongoing |
| Jan 3, 2024 | A randomized, double-blind, placebo-controlled multicenter study to evaluate the efficacy and safety of CAL02 administered intravenously in addition to…Cholesterol-sphingomyelin (CAL02) | Eagle Pharmaceuticals | Ongoing |
| Jan 12, 2023 | Antithrombotic therapy to ameliorate clinical complications in community acquired pneumonia (attacc-cap)Heparin sodium / Lovenox / Fragmin / Innohep | University of Manitoba | Ongoing |
| Sep 15, 2022 | "a phase 1/2, multicenter, randomized, active-controlled, observer-blind, age de-escalation study to evaluate the safety, tolerability, and immunogenicity of…Pneumococcal 25-VALENT conjugate vaccine (ivt PCV-25) | Inventprise Inc. | Pending |
| Jul 28, 2022 | A phase 3 randomized, double-blind, active comparator-controlled, lot-to-lot consistency study to evaluate the safety, tolerability, and immunogenicity of V116…V116 (pneumococcal 21-VALENT conjugate vaccine) / PPSV23 (pneumococcal vaccine,… | Merck & Co. (MSD) | Ongoing |
| Apr 1, 2020 | Randomized, embedded, multifactorial adaptive platform trial for community-acquired pneumonia (remap-cap)Heparin sodium / Lovenox / Fragmin / Innohep / Vitamin C / Simvastatin /… | Unity Health Toronto | Ongoing |
| Sep 28, 2017 | A multicenter, randomized, double-blind, parallelgroup, clinical study of S-649266 compared with meropenem for the treatment of hospital-acquired bacterial…Cefiderocol (S-649266)/ Meropenem | Shionogi | Closed |
| Jan 5, 1999 | MepronPrevention of PCP in patients who are intolerant to trimethoprim-sulfamethoxazole. | Glaxo Wellcome Research and Development | Approved |
| Dec 17, 1993 | NeutrexinConcurrent leucovorin administration as an alternative therapy for the treatment of moderate to severe PCP in immunocompromised patients… | Medimmune Oncology, Inc. | Approved |
| Nov 25, 1992 | MepronFor the acute oral treatment of mild to moderate Pneumocystis carinii pneumonia in patients who are intolerant to… | Glaxo Wellcome Inc. | Approved |
| Jun 15, 1989 | NebupentPrevention of Pneumocystis carinii pneumonia in patients at high risk of developing this disease. | Fujisawa USA, Inc. | Approved |
| Mar 19, 1987 | RetrovirManagement of certain adult patients with symptomatic HIV infection (AIDS and advanced ARC) who have a history of cytologically confirmed… | Glaxo Wellcome Inc. | Approved |
| Oct 16, 1984 | Pentam 300Treatment of Pneumocystis carinii pneumonia. | Fujisawa USA, Inc. | Approved |
| Jan 6, 2010 | Human monoclonal antibody directed against serotype O1…Treatment of pneumonia caused by serotype O1 positive Pseudomonas aeruginosa | Kenta Biotech Limited | Designated |
| Nov 17, 2006 | Pafuramidine maleateTreatment of pneumocystis jiroveci pneumonia | Immtech Pharmaceuticals, Inc. | Designated |
| Sep 18, 2006 | Human monoclonal antibody directed against serotype 011…Treatment of hospital acquired pneumonia caused by serotype 011 positive Pseudomonas aeruginosa | Kenta Biotech Limited | Designated |
| Sep 18, 2006 | rSP-C surfactantFor use in patients with pneumonia or aspiration of gastric contents leading to intubation, mechanical ventilation, and severe oxygen… | Altana Pharma | Designated |
| Dec 20, 1993 | BeractantTreatment of full-term newborn infants with respiratory failure caused by meconium aspiration syndrome, persistent pulmonary hypertension… | Ross Laboratories | Designated |
| Jul 23, 1993 | Primaquine phosphateFor use in combination with clindamycin hydrochloride in the treatment of Pneumocystis carinii pneumonia associated with AIDS. | Sanofi Winthrop, Inc. | Designated |
| Jan 8, 1992 | Dapsone USPFor the combination treatment of Pneumocystis carinii pneumonia in conjunction with trimethoprim. | Jacobus Pharmaceutical Company | Designated |
| Dec 24, 1991 | Dapsone USPProphylaxis for Pneumocystis carinii pneumonia. | Jacobus Pharmaceutical Company | Designated |
| Jan 28, 1991 | Cytomegalovirus immune globulin intravenous (human)For use in conjunction with ganciclovir sodium for the treatment of cytomegalovirus pneumonia in bone marrow transplant patients. | Bayer Corporation | Designated |
| Mar 24, 2025 | CapvaxivePneumococcal polysaccharide conjugate vaccine (21-valent) | Merck Sharp & Dohme B.V. | EMA ↗ |
| Apr 22, 2024 | EmblaveoAztreonam; avibactam | Pfizer Europe MA EEIG | EMA ↗ |
| Mar 21, 2024 | ExblifepCefepime; enmetazobactam | Advanz Pharma Limited | EMA ↗ |
| Feb 14, 2022 | Prevenar 20 (previously Apexxnar)Pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed) | Pfizer Europe MA EEIG | EMA ↗ |
| Dec 13, 2021 | VaxneuvancePneumococcal polysaccharide conjugate vaccine (adsorbed) | Merck Sharp & Dohme B.V. | EMA ↗ |
| Jul 27, 2020 | XenletaLefamulin | Venipharm | EMA ↗ |
| Jul 3, 2020 | VekluryRemdesivir | Gilead Sciences Ireland UC | EMA ↗ |
| Feb 13, 2020 | RecarbrioImipenem; cilastatin; relebactam | Merck Sharp & Dohme B.V. | EMA ↗ |
| Dec 16, 2019 | QuofenixDelafloxacin | A. Menarini Industrie Farmaceutiche Riunite s.r.l. | EMA ↗ |
| Nov 20, 2018 | VaboremMeropenem; vaborbactam | Menarini International Operations Luxembourg S.A. | EMA ↗ |
| Jun 23, 2016 | ZaviceftaCeftazidime; avibactam | Pfizer Ireland Pharmaceuticals Unlimited Company | EMA ↗ |
| Sep 18, 2015 | ZerbaxaCeftolozane; tazobactam | Merck Sharp & Dohme B.V. | EMA ↗ |
| Aug 22, 2012 | ZinforoCeftaroline fosamil | Pfizer Ireland Pharmaceuticals | EMA ↗ |
| Dec 9, 2009 | Prevenar 13Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed) | Pfizer Europe MA EEIG | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA